Aclidinium Bromide

CHEMBL551466 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
564.6 g/mol
LogP
Phase
4

The bromide salt form of aclidinium, a long-acting inhaled bronchodilator used for the ongoing management of COPD. It is administered via a dry powder inhaler twice daily and works by keeping the airways relaxed throughout the day and night. Patients should continue to carry a short-acting rescue inhaler for sudden breathing difficulties.

Khối lượng phân tử

564,6000 g/mol

TPSA

112,00 Ų

Lĩnh vực điều trị

Cơ chế tác dụng

Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C(O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)C(O)(c1cccs1)c1cccs1.[Br-]

InChI

InChI=1S/C26H30NO4S2.BrH/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21;/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2;1H/q+1;/p-1/t20?,22-,27?;/m0./s1

Molecular Formula

C26H30BrNO4S2

HBD / HBA

1 / 7

Liên kết có thể quay

10

Nguyên tử nặng

34

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

The bromide salt form of aclidinium, a long-acting inhaled bronchodilator used for the ongoing management of COPD. It is administered via a dry powder inhaler twice daily and works by keeping the airways relaxed throughout the day and night. Patients should continue to carry a short-acting rescue inhaler for sudden breathing difficulties.

Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.

Yes, Aclidinium Bromide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL551466. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 11519741. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.